I finally had a chance to review that poster's comments from the other site.
The poster states that he could not find the preparation process for DCVAX-L. Well that is ridiculous. It is listed in meticulous detail in these 2 studies. See materials and methods.
This is just the beginning of the poster's failure to study DCVAX.
He also makes the wrong assumption that the enhanced dendritic cells in DCVAX do not amp up the immune response. Again, this is a ridiculous notion. The enhanced dendritic cells used in DCVAX-L amp up the effective expression to B-cells and T-cells. These cells are then able to bolster a prolific response against the tumor with antibodies as well as t-cells. The DCs also invoke other parts of the innate and adaptive immune system. (Ultimately, we expect, DCVax-Direct will beef up this effective response 10 fold, IMO, and any concerns regarding TH1 v. Th2 (thus far unfounded) are also addressed with IL-12 maturation).
His solution? Each pharmaceutical company should use the "one protein one antigen approach."
Give me a break. This is the ultimate wet dream for big pharma. In other words he is effectively suggesting (perhaps unintentionally) that cancer treatment companies share the wealth and never cure cancer. His solution is to let each company find their little subgroup to treat with a very specific one-antigen / one-protein related drug, and thus let the cancer ultimately escape. Again, perhaps unintentionally, his solution will keep cancer and the cancer growth industry alive indefinitely. IMO
He simply never bothered to take the time to study DCVAX-L technology.
Market Data 
Markets 
AI
